Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study
暂无分享,去创建一个
G. Lenz | A. Santoro | A. Nagler | G. Follows | P. Zinzani | W. Kim | S. Leppä | M. Dreyling | B. Childs | F. Morschhauser | F. Hiemeyer | L. Mollica | J. Garcia-Vargas | M. Özcan | J. Demeter | M. Dimou | D. Stevens | K. Bouabdallah | A. Miriyala | M. Kosinova | D. Trevarthen | J. Muñoz | L. Rodrigues
[1] G. Salles,et al. On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors , 2019, Molecular Cancer Therapeutics.
[2] H. Rugo,et al. Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.
[3] I. Flinn,et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] I. Flinn,et al. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study , 2018, American journal of hematology.
[5] I. Flinn,et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. , 2018, The Lancet. Oncology.
[6] M. Ghielmini,et al. Corrigendum: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [Ann Oncol, 27(Suppl 5), (2016), (v83-v90)] doi: 10.1093/annonc/mdw400 , 2017 .
[7] Jonathon B. Cohen,et al. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management. , 2017, Oncology.
[8] G. Lenz,et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Bociek,et al. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma , 2017, Haematologica.
[10] P. Zinzani,et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] F. Toledo,et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Ningshu Liu,et al. Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946) , 2016, ChemMedChem.
[13] E. Winer,et al. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer , 2016, Clinical Cancer Research.
[14] J. Leonard,et al. Idelalisib-associated Colitis: Histologic Findings in 14 Patients , 2015, The American journal of surgical pathology.
[15] V. Gandhi,et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL , 2015, Leukemia.
[16] A. Zelenetz,et al. Management of adverse events associated with idelalisib treatment: expert panel opinion , 2015, Leukemia & lymphoma.
[17] E. Van Cutsem,et al. A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors , 2014, Clinical Cancer Research.
[18] M. Ghielmini,et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] G. Salles,et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.
[20] G. Salles,et al. Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) , 2013 .
[21] A. Haegebarth,et al. BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models , 2013, Molecular Cancer Therapeutics.
[22] J. Baselga,et al. Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. , 2013 .
[23] M. Davids,et al. Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. , 2013, Hematology/oncology clinics of North America.
[24] J. Berlin,et al. Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study , 2012 .
[25] S. Treon,et al. Report from the Sixth International Workshop on Waldenström's Macroglobulinemia. , 2011, Clinical lymphoma, myeloma & leukemia.
[26] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Robbie Loewith,et al. A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.
[28] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.